Welcome to the e-CCO Library!

P564: Low-dose azathioprine improves long-term efficacy of infliximab maintenance treatment in Japanese patients with Crohn's disease
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Nasuno M.*1, Motoya S.1, Sugiyama K.1, Miyakawa M.1, Tanaka H.1, Iida T.2, Onodera K.2, Nakase H.2

Created: Wednesday, 20 February 2019, 10:36 AM
P564: Significant reduction of admission time at the IBD infusion unit by an e-health pre-admission assessment and order system for intravenous therapy
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

E. Hoefkens*1, L. Pouillon1, V. Verheyen2, M. Bronswijk1, A. Van Olmen1, S. Van Dessel3, N. Siborgs4, P. Bossuyt1,5

Created: Friday, 22 February 2019, 9:41 AM
P564: Validation of the IBD-Disk instrument in a Portuguese cohort
Year: 2021
Source: ECCO'21 Virtual
Authors: Silva Mendes, S.(1,2);Ferreira, P.(2);Antunes, P.(1);Gonçalves, M.(1);Leal, T.(1);Gonçalves, B.(1);Rebelo, A.(1);Arroja, B.(1);Caetano, A.C.(1,2);Gonçalves, R.(1);Soares, J.B.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P564: vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease – a meta-analysis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Yiu, T.H.(1)*;Leong, R.(2);Ko, Y.(2);Pudipeddi, A.(2);
Created: Friday, 14 July 2023, 11:05 AM
P565 Efficacy and safety of long-term treatment with ustekinumab in moderate–severe ulcerative colitis patients with delayed response to ustekinumab induction: Results from UNIFI 2-year long-term extension
Year: 2020
Source:

ECCO'20 Vienna

Authors:

B.E. Sands1, M.T. Abreu2, R.W.L. Leong3, C. Marano4, C.D. O’Brien4, H. Zhang5, Y. Zhou5, J. Johanns5, D. Rowbotham6, T. Hisamatsu7, R.P. Arasaradnam8, E. Scherl9, S. Danese10, L. Peyrin-Biroulet11, UNIFI Investigators

Created: Thursday, 30 January 2020, 10:12 AM
P565: Assessments of clinical efficacy and mucosal healing in ulcerative colitis patients undergoing granulomonocytapheresis at different treatment frequencies
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ohmori T., Ohmori S.

Created: Wednesday, 20 February 2019, 10:36 AM
P565: Comparison of the efficacy of adalimumab and ustekinumab for prevention of intestinal fibrosis in bio-naive Crohn's Disease patients
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Biscanin, A.(1,2)*;Tomašić, V.(1);Babic, F.(1);Ćaćić, P.(1);Ogresta Kordej, D.(1);Hrabar, D.(1,2);Kralj, D.(1);Dorosulić, Z.(1);
Created: Friday, 14 July 2023, 11:05 AM
P565: COVID-19 vaccination satisfaction and hesitancy in patients with inflammatory bowel disease: “inside referral center” survey
Year: 2022
Source: ECCO'22
Authors: Todeschini, A.(1);Contaldo, A.(1);Ierardi, E.(1);Di Leo, A.(1);Principi, M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P565: Illness perception as a clinical tool to detect mood disturbances (anxiety or depression) in inflammatory bowel disease patients.
Year: 2021
Source: ECCO'21 Virtual
Authors: De Castro Parga, M.L.(1,2);Pereyra, D.(1);Sanromán, L.(1);Figueira, M.(1);Hernández, V.(1);Pineda, J.(1);Martinez-Cadilla, J.(1);Pereira, S.(1);Rodriguez-Prada, J.I.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P565: Infliximab therapy intensification upon loss of response: what should be the cut-off for trough levels?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

B. Ungar*1, Z. Ben-Shatach1, G. Ben-Haim1, M. Yavzori1, O. Picard1, E. Fudim1, U. Kopylov1, É. Del Tedesco2, P. Veyrard2, P. Stephane2, R. Eliaklim1, S. Ben-Horin1, X. Roblin2

Created: Friday, 22 February 2019, 9:41 AM
P565: Real-world use of azathioprine metabolites changes clinical management of inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Tuson1, L. Wilson1, L. Yang2,3, D. Loomes1,3*

Created: Thursday, 21 February 2019, 9:14 AM
P566 Assessing the efficacy of biologics in ulcerative colitis: A real-life, observational retrospective multicenter study using the propensity score analysis: The ‘A.U.R.O.R.A.’ comparison study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Cassinotti1, N. Mezzina1, D. Di Paolo2, M.V. Lenti3, C. Bezzio4, D. Stradella5, M. Mauri6, V. Zadro1, C. Cortellezzi7, C. Ricci8, V. Casini9, E. Radice10, A. Massari1, S. Ardizzone1, L. Pastorelli2, A. Di Sabatino3, G. Manes4, F. Caprioli11, M. Vecchi11, R. Tari5, P. Occhipinti5, M. Fichera6, P. Invernizzi6, M. Parravicini7, S. Segato7, F. Pace9, P.A. Testoni10, C. Tinelli12, A. De Silvestri12

Created: Thursday, 30 January 2020, 10:12 AM
P566: Colitis due to immunotherapy with anti-PD-1: a case series
Year: 2023
Source: ECCO’23 Copenhagen
Authors: De Ruvo, M.(1)*;Barberio, B.(1);Zingone, F.(1);Bonanno, L.(2);Dal Maso, A.(2);Stefano, F.(2);Chiarion Sileni, V.(3);Savarino, E.V.(1);
Created: Friday, 14 July 2023, 11:05 AM
P566: Effect of polyethylene glycol (PEG) bowel preparation on faecal calprotectin levels in patients with ulcerative colitis
Year: 2018
Source: ECCO '18 Vienna
Authors:

C. Herrera-deGuise*, E. Varela, V. Robles, F. Casellas, N. Borruel

Created: Thursday, 21 February 2019, 9:14 AM
P566: Frequency and type of drug-related side effects necessitating drug cessation in the Swiss inflammatory bowel disease cohort
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Godat S.*1, Fournier N.2, Safroneeva E.3, Marot A.1, Deltenre P.1, Hahnloser D.4, Straumann A.5, Vavricka S.6, Biedermann L.7, Rogler G.8, Schoepfer A.1

Created: Wednesday, 20 February 2019, 10:36 AM
P566: Humoral immune response to mRNA COVID-19 vaccine in Puerto Ricans with IBD does not differ between class of biologics
Year: 2022
Source: ECCO'22
Authors: López Marte, P.(1);Ramos-Tollinchi, L.(1);Rodriguez-Martinó, E.(2);Medina-Prieto, R.(2);Ojeda, S.(3);Santana-Bagur, J.(4);Pantoja, P.(5);Sariol, C.A.(5);Torres, E.A.(2);
Created: Friday, 11 February 2022, 3:56 PM
P566: Impact of induction therapy and clinical remission on resting energy expenditure in children with Crohn’s Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Kornitzer, G.(1);Breton, J.(2);Poinsot, P.(3);Godin, D.(4);Grzywacz, K.(1);Deslandres, C.(1);Groleau, V.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P566: The cost for IBD care during the first 5 years after diagnosis
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Sjöberg*1, U. Karlbom2, M. Thörn3, D. Fawunmi4, A. Rönnblom3

Created: Friday, 22 February 2019, 9:41 AM
P567 Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and inflammatory bowel disease, and relationship with haemoglobin and serum iron
Year: 2020
Source: ECCO'20 Vienna
Authors: S. Howaldt1, I. Jacob2, M. Sampson3, F. Akriche4
Created: Thursday, 30 January 2020, 10:12 AM
Last Modified: Wednesday, 3 March 2021, 4:11 PM by Dauren Ramankulov

Corrigendum:

In the originally published version of this poster presentation, the below corrections have been made.

Upon the original publication, the Results section should read: “250 patients were randomised: 125 to FM and 125 to IV FCM. The primary endpoint was not met. Hb, serum iron and HRQoL all improved following both treatments at Week 12. Improvements in SF-36 physical component summary (PCS) and mental component summary (MCS) scores were slightly greater with FM (difference not statistically significant; Table 1). HRQoL improved across all SF-36 domain scores with both FM and FCM, with no statistically significant differences between treatments (Figure 1). HRQoL (MCS and PCS) improvements were positively associated with increases in Hb and serum iron (Table 1).”.

Upon the original publication, the Conclusion should read: “FM provides HRQoL benefits at least as great as those with IV FCM, and may, therefore, provide an oral alternative to IV iron in patients with IBD.” instead of “FM provides non-inferior efficacy to IV FCM with at least as great a benefit to HRQoL and may, therefore, provide an oral alternative to IV iron in patients with IBD.”.

P567: Could an escalation of therapy or intervention (ETI) calculator be used to triage appointments for patients with ulcerative colitis?
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Walsh*1, L. Matini1, R. Kantschuster1, M. Lepetyukh1, R. Nedescu1, J. Wilson1, O. Brain1, R. Palmer1, S. Keshav1, S. Travis1

Created: Friday, 22 February 2019, 9:41 AM